Full history for every metric is available with a Kvantra account
PCL, Inc. (241820.KQ)
Key financial summary
Financials in KRW| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | KRW bn | 0 | 54 | 46 | 37 | 8 | 1 |
| Operating profit | KRW bn | -27 | |||||
| Net profit | KRW bn | -8 | 20 | -32 | -4 | -20 | -52 |
| EPS reported | KRW | -932.1 | |||||
| Operating cashflow per share | KRW | -281.0 | |||||
| Capex per share | KRW | 2.41 | |||||
| FCF per share | KRW | -283.4 | |||||
| Free cash flow | KRW bn | -16 | |||||
| Net debt | KRW bn | 6 | |||||
| Book value equity | KRW bn | 7 | |||||
| Book value per share | KRW | 126.7 | |||||
| Number of shares | m | 56.15 | |||||
| DPS (TTM paid) | KRW | 0.00 |
Financial summary
Financials in KRW| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 4.37 | |||||
| P/S LTM | x | 24.96 | |||||
| P/FCF LTM | x | -1.95 | |||||
| EV/EBITDA LTM | x | -0.82 | |||||
| EV/Sales LTM | x | 32.13 | |||||
| Earnings Yield LTM | % | -168.25% | |||||
| FCF Yield | % | -51.15% | |||||
| Quality | |||||||
| ROE | % | -735.47% | |||||
| ROIC | % | -144.59% | |||||
| Operating margin | % | -2175.4% | |||||
| Gross margin | % | -827.34% | |||||
| FCF/Sales | % | -1276.9% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | -85.22% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -1.45 | |||||
| Net Debt/EBITDA | x | -0.18 | |||||
| EBIT/Net interest | x | -22.55 | |||||
| Net debt/market cap | % | 20.48% | |||||
| Net debt/Equity | x | 0.90 | |||||
| Gross debt/equity | x | 1.54 | |||||
Company overview
PCL, Inc. specializes in providing sophisticated multiplex in vitro diagnostic (IVD) solutions, encompassing both diagnostic products and specialized platform services. The company's primary offerings include comprehensive multiplex kits designed to detect antibodies to Human Immunodeficiency Virus (HIV) types 1 and 2, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human T-lymphotropic Virus (HTLV) types 1 and 2. These kits also identify specific antigens such as HIV p24, HCV core, and HBV surface markers in human serum or plasma samples. In addition to these, PCL markets Ai, a rapid diagnostic test kit capable of typing influenza A and B strains; Cancer6, a screening kit for multiple tumor biomarkers; and the sciLINER LATERAL FLOW DISPENSER, an advanced dispensing device for membrane materials featuring active visual drop volume control. Beyond its product portfolio, PCL offers valuable platform services. These include a sol-gel spotting service, which immobilizes client-specified materials using the proprietary SolB reagent, and an SG ID service, providing customers with identified molecules of interest securely immobilized within the SolB reagent. PCL, Inc. is headquartered in Seoul, South Korea.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
PCL, Inc. (241820.KQ)
PCL, Inc. specializes in providing sophisticated multiplex in vitro diagnostic (IVD) solutions, encompassing both diagnostic products and specialized platform services. The company's primary offerings include comprehensive multiplex kits designed to detect antibodies to Human Immunodeficiency Virus (HIV) types 1 and 2, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human T-lymphotropic Virus (HTLV) types 1 and 2. These kits also identify specific antigens such as HIV p24, HCV core, and HBV surface markers in human serum or plasma samples. In addition to these, PCL markets Ai, a rapid diagnostic test kit capable of typing influenza A and B strains; Cancer6, a screening kit for multiple tumor biomarkers; and the sciLINER LATERAL FLOW DISPENSER, an advanced dispensing device for membrane materials featuring active visual drop volume control. Beyond its product portfolio, PCL offers valuable platform services. These include a sol-gel spotting service, which immobilizes client-specified materials using the proprietary SolB reagent, and an SG ID service, providing customers with identified molecules of interest securely immobilized within the SolB reagent. PCL, Inc. is headquartered in Seoul, South Korea.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free